Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts

Fig. 1

Hormone therapy mitigates NFT load and p-tau concentrations in post-menopausal females. HT+ females demonstrated significantly lower tau-PET SUVRs in Braak I-II ROIs (TRIAD: P < 0.05, Hedges’ g = 0.73), Braak III-IV ROIs (TRIAD: P < 0.0001, Hedges’ g = 0.74; ADNI: P < 0.01, Hedges’ g = 0.45) and Braak V-VI ROIs (TRIAD: P < 0.0001, Hedges’ g = 0.69; ADNI: P < 0.01, Hedges’ g = 0.37) compared to HT- females. HT + females also showed significantly lower CSF p-tau181 (P < 0.001) and plasma p-tau181 (P < 0.0001) concentrations

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193